MedTrace Logo

PegvisOMant and the Immune SystEm (PROMISE)

NCT05069324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2025-01-16

No results posted yet for this study

Summary

This is a prospective observational pilot study for the evaluation of immune cells phenotype in acromegalic patients in comparison with a control population and to investigate the impact of disease control and different medical treatments (particularly Pegvisomant) on immune function and its implication on insulin resistance, metabolic complications and fat accumulation.

Conditions

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Andrea M Isidori, PHD · Department of Experimental Medicine, "Sapienza" University of Rome

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-29
Primary Completion
2024-12-15
Completion
2024-12-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05069324 on ClinicalTrials.gov